

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 108236.130)

In re Application of: Jeffrey G. Moore 10/083,936

Not Yet Assig Group Art Unit: 1623

Examiner:

Filing Date:

For:

February 27, 2002

COMPOSITION AND METHOD FOR PROTECTING TISSUES AND CELLS FROM DAMAGE,

AND FOR REPAIRING DAMAGED TISSUES

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 100. 6. 2005

Patricia Corrigan

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for filing in the above-identified patent application are the following documents:

- 1. Information Disclosure Statement (2 pages);
- 2. Form PTO-1449 (2 pages);
- 3. Reference as Cited (31);
- 4. Certificate of First Class Mailing, and;
- 5. Return Postcard.

No fees are believed to be due in connection with this submission. However, please charge any fees that might be due or credit any overpayment to our Deposit Account No. 08-0219.

Respectfully submitted,

Date: Fes. 6. 2003

HALE AND DORR LLP

60 State Street Boston, MA 02109 (617) 526-6000

(617) 526-5000 (Facsimile)

Nancy Chiu, Ph.D., Reg. No. 43,545

Attorney/Agent for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 108236.130)

In re Application of: Jeffrey G. Moore

Examiner:

Not Yet Assign

Serial No.

10/083,936

Group Art Unit: 1623

Filing Date:

February 27, 2002

For:

COMPOSITION AND METHOD FOR PROTECTING TISSUES AND CELLS FROM

DAMAGE, AND FOR REPAIRING DAMAGED TISSUES

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: Feb. 6 2003

Patricia Corrigan

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner:

Pursuant to 37 C.F.R. § 1.97-98, Applicant hereby makes of record the documents listed on the attached Form PTO-1449, and encloses copies herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom. In this regard, it is requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office Communication.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due. The Commissioner, however, is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. <u>08-0219</u>.

Date: Fes. 6. 2003

Respectfully submitted,

Nancy Chiu, Ph.D.

Registration No.43,545

Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109

Tel: (617) 526-6548 Fax: (617) 526-5000 Sept For, PTO-1449

NFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 108236.130 Application Number 10/083,936

Applicant Moore, Jeffrey G.

Group Art Unit Filing Date 02/27/2002 1623 OF 2 1 Sheet

		U.S	S. Patent Docume			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HALLIAGE	4,808,611	02/28/89	Cosman	514	12	
	5,186,931	02/16/93	Kishimoto, et al	424	85.2	
	5,472,867	12/05/95	Kanz , et al	435	240.25	
	5,545,820	08/13/96	Gatehouse, et al	800	205	
	6,084,060	07/04/20	Moore	530	200	

		Forei	gn Patent Docur	nents		•	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO
	WO 98 59038	30/12/98	WIPO				
	WO 98 25457	18/06/98	WIPO				ļ
	WO 97 41224	06/11/97	WIPO				<u> </u>
	WO 95 00554	05/01/95	WIPO				
	WO 01 49851	30/12/99	WIPO				

1	
	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
	COLUCCI, G., et al., "cDNA cloning of FRIL, a lectin from <i>Dolichos lablab</i> , that preserves hematopoietic progenitors
	GABIUS, H.J. "Non-Carbohydrate Binding Partners/Domains of Animal Lectins", Int. J. Biochem. 20(4):403-477,
	GOWDA, L.R., et al., "The Complete Primary Structure of a Unique Mannose/Glucose-Specific Lectin from Field Bean", The Journal of Biological Chemistry 269(29):18789-18793, 1994
	HAO, Q.L., et al., "Extended Long-Term Culture Reveals a Highly Quiescent and Primitive Human Hematopoletic
	HOFFMAN, L.M., et al., "Molecular Cloning of <i>Phaseolus Vulgaris</i> Lectin mRNA and Use of CDNA as a Probe to
	KOLLET, O., et al., "The plant lectin FRIL supports prolonged in vitro maintenance of quiescent numan cold blood
	LENFANT, M., et al., "Inhibitor of Hematopoietic Pluripotent Stem Cell Proliferation: Purification and Determination of
	MO H ot al. "Purification and characterization of Dolichos lablab lectin", Glycobiology 9(2), 173-179, 1999
	MOORE, J.G., et al., "A new lectin in red kidney beans called PvFRIL stimulates proliferation of NIH 3T3 cells expressing the Flt3 receptor", Biochimica Et Biophysica Acta 1475 : 216-224, 2000
	MOORE, J.G., et al., "Preservation of hematopoietic progenitors for prolonged periods in suspension cultures by Elizabeta reconstruinteracting lectin (FRIII), a new lectin identified in red kidney beans", Blood 90 :P 428A, 1997 (39 th
	annual meeting of the American Society of Hematology: San Diego, California, December 5-9, 1997) PUSZTAI, A., "Dietary lectins are metabolic signals for the gut and modulate immune and hormone functions",
	European Journal of Clinical Nutrition 47, 691-699, 1993
	SHAH, A.J., et al., "Flt3 Ligand Induces Proliferation of Quiescent Human Bone Marrow CD34 ⁺ CD38 Cells and Maintains Progenitor Cells in Vitro", Blood 87(9) :3563-3570, 1996
	CHADON N. et al. "Lectins as Cell Recognition Molecules". Science 246:227-234, 1989
	SMALL, D., et al., STK-1, the Human Hmolog of Flk-2/Flt-3, is Selectively Expressed in CD34 ⁺ Human Bone Marrow

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citat citation if not conformance and not considered. Include copy with	I ion is in conformance with MPEP § 609: Draw Line through next communication to applicant.

ADE	
	Cells and is Involved in the Proliferation of Early Progenitor/Stem Cells" Proc. Natl. Acad. Sci. 91:459-463, 1994
L	STUBBS, M.E., et al., "Production of Pea Lectin in Escherichia coli", J. Biol. Chem. 261(14):6141-6144, 1986
	STUBBS, M.E., et al., Production of Fea Eccurity disease to distance lection." EERS Letters 397, 139-142, 1996
	TCHERNYCHEV, B., et al., "Natural human antibodies to dietary lectins", FEBS Letters 397, 139-142, 1996
	VAN EIJSDEN, R.R., et al., "Mutational Analysis of Pea Lectin. Substitution of Ash125 for Asp in the
	WANG, Q., et al., "Identification of intact peanut lectin in peripheral venous blood", The Lancet 352, 1831-1832, 1998
	WANG, Q., et al., "Identification of intact peanut tectiff in peripheral visitods Dock Propried During Ex Vivo
	YOUNG, J.C., et al., "Retention of Quiescent Hematopoietic Cells with High Proliferative Potential During Ex Vivo
	l o o. 11 O. 11
	ZIPORI, D., "Regulation of Hemopoiesis by Cytokines that Restrict Options for Growth and Differentiation", Cancer
1	A 11 A/=\.00F 044 4000
	ZIPORI, D., "The Renewal and Differentiation of Hemopoietic Stem Cells", The FASEB Journal 6 :2691-2697, 1992
	Zir Oni, D., The Honorway and Dimensional Control

EXAMINER

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

DATE CONSIDERED